NASAREL Drug Patent Profile

Which patents cover Nasarel, and what generic alternatives are available?

Nasarel is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in NASAREL is flunisolide. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the flunisolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nasarel

A generic version of NASAREL was approved as flunisolide by BAUSCH on February 20^th, 2002.

Summary for NASAREL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
Patent Applications:	5,230
DailyMed Link:	NASAREL at DailyMed

US Patents and Regulatory Information for NASAREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995		DISCN	No	No

Expired US Patents for NASAREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995
Teva Branded Pharm	NASAREL	flunisolide	SPRAY, METERED;NASAL	020409-001	Mar 8, 1995

International Patents for NASAREL

See the table below for patents covering NASAREL around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	7603131
Finland	88459
Canada	1288048	STEROIDE EN SOLUTION AQUEUSE POUR ADMINISTRATION NASALE (AQUEOUS STEROID FORMULATIONS FOR NASAL ADMINISTRATION)
Finland	872231
Germany	2661037
South Korea	950008308
New Zealand	180946	6 -FLUORO-11 ,21-DIHYDROXY-16 ,17 -ISOPROPYLIDENEDI-OXY-PREGNA-1,4-DIEN-3,20-DIONE HAVING POLYMORPHIC FORM-FORM A

NASAREL Market Analysis and Financial Projection Experimental

Nasal Drug Delivery Technology: The Rise of NASAREL and Market Dynamics

Introduction to Nasal Drug Delivery Technology

Nasal drug delivery technology has emerged as a significant breakthrough in patient care, offering non-invasive administration methods that enhance patient compliance and bioavailability. This technology is gaining traction due to its efficacy in treating various conditions, including chronic respiratory diseases and neurological disorders.

Market Size and Growth Projections

The global nasal drug delivery technology market is expected to experience substantial growth over the next few years. Here are some key projections:

• The market is anticipated to grow from approximately USD 4.4 billion in 2024 to around USD 7.8 billion by 2031, achieving a compound annual growth rate (CAGR) of about 8.4%[1].
• Another estimate suggests the market will expand from USD 71.89 billion in 2022 to USD 127.12 billion by 2030, with a CAGR of 7.45%[4].

Drivers of Market Growth

Several factors are driving the growth of the nasal drug delivery technology market:

Increasing Demand for Non-Invasive Methods

Patients are increasingly seeking alternative medicine delivery methods that are less invasive and more comfortable. Nasal drug delivery fits this need perfectly, enhancing patient compliance and reducing the discomfort associated with traditional methods like injections[3].

Advancements in Delivery Technologies

Innovations such as advanced formulations and micro-needle systems are boosting the adoption of nasal drug delivery. These advancements improve the efficacy and ease of use of nasal drugs, making them more appealing to both patients and healthcare providers[1].

Rising Prevalence of Chronic Diseases

The growing prevalence of chronic respiratory diseases and other conditions is a significant driver of market growth. Chronic diseases, which affect a substantial portion of the population, require efficient and effective treatment methods, and nasal drug delivery is increasingly being recognized as a viable option[4].

Need for Efficient Vaccination Solutions

The need for efficient vaccination solutions, particularly highlighted during the COVID-19 pandemic, has also propelled the growth of nasal drug delivery technology. Nasal administration of vaccines offers a promising alternative to traditional injection methods[1].

Key Segments and Products

The nasal drug delivery market is segmented into various categories based on dosage forms, container types, and therapeutic applications.

Dosage Forms

• Nasal Sprays: These are widely used for conditions such as allergies and respiratory diseases.
• Nasal Drops: Expected to expand at the fastest CAGR due to their affordability and treatment success rates[4].
• Nasal Gels and Powders: Also gaining popularity due to their ease of use and effectiveness.

Container Types

• Non-Pressurized Containers: Dominated the market with a revenue share of over 85.0% in 2022, primarily used for nasal drops, powders, and gels[4].

Therapeutic Applications

• Nasal Congestion and Rhinitis: Common applications for nasal drugs.
• Asthma and Other Respiratory Conditions: Nasal drugs are increasingly used to manage these conditions.
• Neurological Disorders: Products like VALTOCO (diazepam nasal spray) are used for acute treatment of seizure clusters in epilepsy patients[2].

Regional Market Analysis

The global nasal drug delivery technology market is geographically diverse, with different regions contributing significantly to its growth.

• North America: Dominated the market with a share of 34.85% in 2022, driven by high disease prevalence and significant R&D investments[4].
• Asia-Pacific: Countries like China, India, and South Korea are forecast to grow at a high CAGR, driven by increasing healthcare spending and a growing patient population[5].

Financial Trajectory and Investments

The financial trajectory of companies involved in nasal drug delivery technology is robust, with significant investments being made to advance these technologies.

• Neurelis, Inc.: Closed a $114 million Series D financing round to support the commercialization of VALTOCO (diazepam nasal spray) and to expand its neuroscience pipeline[2].

Case Study: VALTOCO (Diazepam Nasal Spray)

VALTOCO, developed by Neurelis, Inc., is a prime example of the success of nasal drug delivery technology in the market.

• Market Impact: VALTOCO has become a trusted brand for people with epilepsy, providing an effective and convenient treatment option for acute seizure clusters[2].
• Financial Impact: The $114 million Series D financing round has been instrumental in enhancing the growth and commercial penetration of VALTOCO, as well as supporting the development of Neurelis’s neuroscience pipeline[2].

Challenges and Opportunities

While the nasal drug delivery technology market is growing rapidly, it also faces some challenges and presents several opportunities.

Challenges

• Regulatory Hurdles: Ensuring compliance with regulatory standards can be a challenge for new entrants in the market.
• Technological Barriers: Developing advanced formulations and delivery systems requires significant R&D investments.

Opportunities

• Expanding Therapeutic Applications: There is a growing opportunity to use nasal drug delivery for a wider range of therapeutic applications beyond respiratory and neurological conditions.
• Global Market Expansion: Emerging markets in Asia-Pacific and other regions offer significant growth opportunities due to increasing healthcare spending and a growing patient population[5].

Key Takeaways

• The global nasal drug delivery technology market is expected to grow significantly, driven by the demand for non-invasive methods, advancements in technology, and the rising prevalence of chronic diseases.
• Key segments include nasal sprays, drops, gels, and powders, with non-pressurized containers dominating the market.
• Regional markets, particularly North America and Asia-Pacific, are crucial for the growth of this market.
• Significant investments are being made to advance these technologies, as seen with Neurelis, Inc.’s VALTOCO.

FAQs

1. What is the projected market size of the nasal drug delivery technology market by 2031? The global nasal drug delivery technology market is expected to grow from approximately USD 4.4 billion in 2024 to around USD 7.8 billion by 2031[1].

2. What are the key drivers of the nasal drug delivery technology market? The key drivers include increasing demand for non-invasive methods, advancements in delivery technologies, and the rising prevalence of chronic diseases[1][4].

3. Which segment is expected to expand at the fastest CAGR in the nasal drug delivery market? The nasal drop segment is estimated to expand at the fastest CAGR due to its affordability and treatment success rates[4].

4. What is the significance of VALTOCO (diazepam nasal spray) in the market? VALTOCO has become a trusted brand for people with epilepsy, providing an effective and convenient treatment option for acute seizure clusters, and its commercial success has been supported by significant financing rounds[2].

5. Which regions are forecast to grow at a high CAGR in the nasal drug delivery technology market? Regions such as Asia-Pacific, particularly China, India, and South Korea, are forecast to grow at a high CAGR due to increasing healthcare spending and a growing patient population[5].

Sources

1. Market Research Intellect - Nasal Drug Delivery Technology Market Breakthrough in Patient Care Projected Market Growth to USD 7.8 Billion by 2031[1].
2. Neurelis, Inc. - Neurelis Announces Close of $114 Million Series D Financing Round to Advance Neuroscience Focus[2].
3. SNS Insider - Nasal Drug Delivery Market Size & Industry Growth 2024-2031[3].
4. Grand View Research - Nasal Drug Delivery Technology Market Size Analysis Report 2030[4].
5. PR Newswire - Global Intranasal Drug Delivery Strategic Markets Report 2023-2030[5].